• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

作者信息

Bernard Elsa, Nannya Yasuhito, Hasserjian Robert P, Devlin Sean M, Tuechler Heinz, Medina-Martinez Juan S, Yoshizato Tetsuichi, Shiozawa Yusuke, Saiki Ryunosuke, Malcovati Luca, Levine Max F, Arango Juan E, Zhou Yangyu, Solé Francesc, Cargo Catherine A, Haase Detlef, Creignou Maria, Germing Ulrich, Zhang Yanming, Gundem Gunes, Sarian Araxe, van de Loosdrecht Arjan A, Jädersten Martin, Tobiasson Magnus, Kosmider Olivier, Follo Matilde Y, Thol Felicitas, Pinheiro Ronald F, Santini Valeria, Kotsianidis Ioannis, Boultwood Jacqueline, Santos Fabio P S, Schanz Julie, Kasahara Senji, Ishikawa Takayuki, Tsurumi Hisashi, Takaori-Kondo Akifumi, Kiguchi Toru, Polprasert Chantana, Bennett John M, Klimek Virginia M, Savona Michael R, Belickova Monika, Ganster Christina, Palomo Laura, Sanz Guillermo, Ades Lionel, Della Porta Matteo Giovanni, Smith Alexandra G, Werner Yesenia, Patel Minal, Viale Agnès, Vanness Katelynd, Neuberg Donna S, Stevenson Kristen E, Menghrajani Kamal, Bolton Kelly L, Fenaux Pierre, Pellagatti Andrea, Platzbecker Uwe, Heuser Michael, Valent Peter, Chiba Shigeru, Miyazaki Yasushi, Finelli Carlo, Voso Maria Teresa, Shih Lee-Yung, Fontenay Michaela, Jansen Joop H, Cervera José, Atsuta Yoshiko, Gattermann Norbert, Ebert Benjamin L, Bejar Rafael, Greenberg Peter L, Cazzola Mario, Hellström-Lindberg Eva, Ogawa Seishi, Papaemmanuil Elli

机构信息

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Nat Med. 2021 Mar;27(3):562. doi: 10.1038/s41591-021-01253-5.

DOI:10.1038/s41591-021-01253-5
PMID:33564192
Abstract
摘要

相似文献

1
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.作者更正：TP53等位基因状态对骨髓增生异常综合征基因组稳定性、临床表现及预后的影响
Nat Med. 2021 Mar;27(3):562. doi: 10.1038/s41591-021-01253-5.
2
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.作者更正：TP53等位基因状态对骨髓增生异常综合征基因组稳定性、临床表现及预后的影响
Nat Med. 2021 May;27(5):927. doi: 10.1038/s41591-021-01367-w.
3
[Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].[骨髓增生异常综合征患者TP53基因突变与缺失的临床意义及预后价值]
Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):215-221. doi: 10.3760/cma.j.issn.0253-2727.2019.03.010.
4
Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.低级别骨髓增生异常综合征和非复杂核型骨髓增生异常综合征中 TP53 突变的特征。
Eur J Haematol. 2017 Dec;99(6):536-543. doi: 10.1111/ejh.12971. Epub 2017 Oct 20.
5
Targeting TP53 Mutations in Myelodysplastic Syndromes.针对骨髓增生异常综合征中的 TP53 突变。
Hematol Oncol Clin North Am. 2020 Apr;34(2):421-440. doi: 10.1016/j.hoc.2019.11.004. Epub 2019 Dec 12.
6
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.治疗相关的骨髓增生异常综合征和急性髓系白血病中的TP53突变特征与原发性疾病相似。
J Hematol Oncol. 2015 May 8;8:45. doi: 10.1186/s13045-015-0139-z.
7
[Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].[伴有环形铁粒幼细胞的骨髓增生异常综合征患者基因突变的特征及临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):379-386. doi: 10.3760/cma.j.issn.0253-2727.2020.05.004.
8
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.甲基化抑制剂治疗的骨髓增生异常综合征中TP53突变的临床意义
Oncotarget. 2016 Mar 22;7(12):14172-87. doi: 10.18632/oncotarget.7290.
9
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.TP53过表达是伴有纤维化的初发骨髓增生异常综合征的一个独立不良预后因素。
Br J Haematol. 2015 Oct;171(1):91-9. doi: 10.1111/bjh.13529. Epub 2015 Jun 30.
10
Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports.低危骨髓增生异常综合征患者TP53基因新突变的存在：两例报告
J Med Case Rep. 2017 May 21;11(1):143. doi: 10.1186/s13256-017-1301-8.

引用本文的文献

1
Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma.鉴定致突变衍生的长链非编码 RNA 基因组不稳定性特征，以促进肝细胞癌的临床转归。
Comput Math Methods Med. 2021 Nov 11;2021:1205029. doi: 10.1155/2021/1205029. eCollection 2021.